SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Pacific Biosciences of California, Inc. – ‘S-8’ on 11/19/21

On:  Friday, 11/19/21, at 7:02pm ET   ·   As of:  11/22/21   ·   Effective:  11/22/21   ·   Accession #:  1299130-21-225   ·   File #:  333-261251

Previous ‘S-8’:  ‘S-8’ on 9/20/21   ·   Next:  ‘S-8’ on 2/28/22   ·   Latest:  ‘S-8’ on 2/29/24   ·   3 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

11/22/21  Pacific Biosciences of Cal, Inc.  S-8        11/22/21    4:171K

Registration Statement – Securities for an Employee Benefit Plan   —   Form S-8   —   SA’33

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-8         Registration Statement - Securities for an          HTML     81K 
                Employee Benefit Plan                                            
 2: EX-5.1      Opinion of Counsel re: Legality                     HTML     14K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML      6K 
 4: EX-23.3     Consent of Expert or Counsel                        HTML      6K 


‘S-8’   —   Registration Statement – Securities for an Employee Benefit Plan

Document Table of Contents

Page (sequential)   (alphabetic) Top
 
11st Page  –  Filing Submission
"Power of Attorney (contained on signature page hereto)

This is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:   C: 
  S-8  

As filed with the Securities and Exchange Commission on November 22,  2021



Registration No. 333-

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S-8 

REGISTRATION STATEMENT Under The Securities Act of 1933

 

Pacific Biosciences of California, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 



 

 

Delaware

 

16-1590339

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)



1305 O’Brien Drive

Menlo Park, CA 94025

(Address of Principal Executive Offices) (Zip Code)

  

 

Pacific Biosciences of California, Inc. 2020 Inducement Equity Incentive Plan 

(Full title of the plan)

Christian O. Henry

Chief Executive Officer and President

1305 O’Brien Drive

Menlo Park, CA 94025

(Name and address of agent for service)

(650) 521-8000

(Telephone number, including area code, of agent for service)

Copies to:

Donna M. Petkanics

Andrew D. Hoffman

Wilson Sonsini Goodrich & Rosati, P.C.

650 Page Mill Road

Palo Alto, CA 94304

(650) 493-9300

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.



 

 

 

 

 

 



 

 

 

 

 

 

Large accelerated filer

 

 

Accelerated filer

 



 

 

 

Non-accelerated filer

 

 

Smaller reporting company

 



 

 

 



 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  

 


 

CALCULATION OF REGISTRATION FEE

 



 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

Title of securities

to be registered

 

Amount

to be

registered (1)

 

Proposed

maximum

offering price

per share

 

Proposed

maximum
aggregate

offering price

 

Amount of

registration fee

Common stock, $0.001 par value per share, reserved for issuance pursuant to equity awards outstanding under the 2020 Inducement Equity Incentive Plan

 

360,000 (2)

 

$25.92 (3)

 

    $9,331,200.00 

 

 $865.00

 

 





(1)

Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 (the “Registration Statement”) shall also cover any additional shares of common stock of Pacific Biosciences of California, Inc. (the “Registrant”) that may be issued pursuant to the 2020 Inducement Equity Incentive Plan (the “Inducement Plan”), by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration which results in an increase in the number of the outstanding shares of common stock of the Registrant.

(2)

Reflects 360,000 additional shares of common stock reserved for issuance pursuant to the Inducement Plan, as amended, as a result of an increase approved by Registrant’s board of directors.

(3)

Estimated in accordance with Rule 457(c) and (h) under the Securities Act, solely for purposes of calculating the registration fee on the basis of $25.92, the average of the high and low prices of Registrants common stock as reported on the NASDAQ Global Select Market on November 18, 2021. 



 


EXPLANATORY NOTE



Pursuant to General Instruction E of Form S-8, the Registrant is filing this Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (the “Commission”) to register 360,000 additional shares of the Registrant’s common stock  reserved for issuance pursuant to the Inducement Plan. This Registration Statement hereby incorporates by reference the contents of the Registrant’s registration statement on Form S-8 filed with the Commission on December 4, 2020 (Registration No. 333-251153) and the contents of the Registrant’s registration statement on Form S-8 filed with the Commission on April 19, 2021 (Registration No. 333-255342).



PART I

INFORMATION REQUIRED IN THE PROSPECTUS

The documents containing the information specified in Item 1 and Item 2 of this Registration Statement, as amended, will be sent or given to employees, officers, directors or others as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the Securities Act). In accordance with the rules and regulations of the Commission and the instructions to the Registration Statement, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424.

PART II

INFORMATION REQUIRED IN REGISTRATION STATEMENT

 



 

Item 3.

Incorporation of Documents by Reference.



Pacific Biosciences of California, Inc. (the Registrant) hereby incorporates by reference into this Registration Statement the following documents previously filed with the Commission:

(1) The Registrants Annual Report on Form 10-K for its fiscal year ended December 31, 2020, filed with the Commission on February 26, 2021 pursuant to Section 13(a) of the Securities Exchange Act of 1934, as amended (the Exchange Act);


 

(2) All other reports filed with the Commission pursuant to Sections 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrants Annual Report referred to in (1) above (other than the portions of these documents not deemed to be filed); and

(3) The description of the Registrants Common Stock contained in the Registrants Registration Statement on Form 8-A (File No. 001-34899) filed with the Commission on October 6, 2010, pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents.



Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. 





 

Item 4.

Description of Securities.



Not applicable.

 



 

Item 5.

Interests of Named Experts and Counsel.



Not applicable.





 

Item 6.

Indemnification of Directors and Officers.



Section 145 of the Delaware General Corporation Law authorizes a corporation’s board of directors to grant, and authorizes a court to award, indemnity to officers, directors and other corporate agents.

As permitted by Section 102(b)(7) of the Delaware General Corporation Law, the Registrant’s certificate of incorporation includes provisions that eliminate the personal liability of its directors for monetary damages for breach of their fiduciary duty as directors. To the extent Section 102(b)(7) is interpreted, or the Delaware General Corporation Law is amended, to allow similar protections for officers of a corporation, such provisions of the Registrant’s certificate of incorporation shall also extend to those persons.



In addition, as permitted by Section 145 of the Delaware General Corporation Law, the bylaws of the Registrant to be effective upon completion of this offering provide that:





 

The Registrant shall indemnify its directors and officers for serving the Registrant in those capacities or for serving other business enterprises at the Registrant’s request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful.

 

The Registrant may, in its discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.

 

The Registrant is required to advance expenses, as incurred, to its directors and officers in connection with defending a proceeding, except that such director or officer shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.

 

The Registrant will not be obligated pursuant to the bylaws to indemnify a person with respect to proceedings initiated by that person, except with respect to proceedings authorized by the Registrant’s board of directors or brought to enforce a right to indemnification.

 

The rights conferred in the bylaws are not exclusive, and the Registrant is authorized to enter into indemnification agreements with its directors, officers, employees and agents and to obtain insurance to indemnify such persons.

 

The Registrant may not retroactively amend the bylaw provisions to reduce its indemnification obligations to directors, officers, employees and agents.


 



The Registrant’s policy is to enter into separate indemnification agreements with each of its directors and officers that provide the maximum indemnity allowed to directors and executive officers by Section 145 of the Delaware General Corporation Law and also provides for certain additional procedural protections.

These indemnification provisions and the indemnification agreements entered into between the Registrant and its officers and directors may be sufficiently broad to permit indemnification of the Registrant’s officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act.





 

Item 7.

Exemption from Registration Claimed.



Not applicable.





 

Item 8.

Exhibits.







 

 



 

 

Exhibit

Number

 

Description



 

4.1

 

Specimen Common Stock Certificate of Registrant (which is incorporated herein by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (Registration No. 333-168858), as declared effective on October 26, 2010)



 

4.2

 

Description of the Registrant’s securities registered under Section 12 of the Exchange Act (which is incorporated herein by reference to Exhibit 4.2 to the Registrant’s Form 10-K filed on February 28, 2020)



 

 

4.3+

 

Pacific Biosciences of California, Inc. 2020 Inducement Equity Incentive Plan and related forms of agreement thereunder (incorporated by reference from Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on November 19, 2021)



 

5.1

 

Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation  



 

23.1

 

Consent of Independent Registered Public Accounting Firm    



 

23.2

 

Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1 hereto) 



 

 

23.3

 

Consent of KPMG LLP, Independent Auditors of Omniome, Inc.



 

24.1

 

Power of Attorney (contained on signature page hereto) 



+  Indicates management contract or compensatory plan, contract or arrangement.





 

Item 9.

Undertakings.

A. The undersigned Registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the


 

Calculation of Registration Fee table in the effective registration statement; and

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

Provided, however, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.



B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrants annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plans annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


 

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Menlo Park, State of California, on November 19, 2021.  





 

 



 

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.



 

 



By:

/s/ Michele Farmer



 

Michele Farmer



 

Vice President and Chief Accounting Officer



POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Christian O. Henry, Susan G. Kim, Brett Atkins and Michele Farmer, jointly and severally, as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign the Registration Statement on Form S-8 of Pacific Biosciences of California, Inc. and any or all amendments (including post-effective amendments) thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.


 

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated below:

 

e

 

 

 

 



 

 

 

 

Signature

 

Title

 

Date



 

 

/s/ Christian O. Henry

Christian O. Henry

 

 

Director, Chief Executive Officer

and President (Principal Executive Officer)

 

November 19, 2021



 

 

/s/ Susan G. Kim

Susan G. Kim

 

Chief Financial Officer

(Principal Financial Officer)

 

November 19, 2021



 

 

 

 

/s/ Michele Farmer

Michele Farmer

 

Vice President and Chief Accounting Officer (Principal Accounting Officer)

 

November 19, 2021

/s/ John F. Milligan

John F. Milligan

 

Chairman of the Board of Directors

 

November 19, 2021



 

 

 

 

/s/ David Botstein

David Botstein

 

Director

 

November 19, 2021



 

 

 

 

/s/ William W. Ericson

William W. Ericson

 

Director

 

November 19, 2021



 

 

 

 

/s/ Hannah A. Valantine

Hannah A. Valantine

 

Director

 

November 19, 2021



 

 

 

 

/s/ Randall S. Livingston

Randall S. Livingston

 

Director

 

November 19, 2021



 

 

/s/ Marshall L. Mohr

Marshall L. Mohr

 

Director

 

November 19, 2021

/s/ Kathy Ordoñez

Kathy Ordoñez

 

Director

 

November 19, 2021



 

 

/s/ Lucy Shapiro

Lucy Shapiro

 

Director

 

November 19, 2021





Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘S-8’ Filing    Date    Other Filings
Filed as of / Effective on:11/22/21
Filed on:11/19/218-K
4/19/218-K,  S-3ASR,  S-8
2/26/2110-K,  4,  S-8
12/31/2010-K,  SD
12/4/208-K,  S-8
10/6/108-A12B
 List all Filings 


3 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/19/21  Pacific Biosciences of Cal, Inc.  8-K:5      11/19/21   11:760K
 2/28/20  Pacific Biosciences of Cal, Inc.  10-K       12/31/19   80:11M
10/01/10  Pacific Biosciences of Cal, Inc.  S-1/A¶                 6:4M                                     Donnelley … Solutions/FA
Top
Filing Submission 0001299130-21-000225   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., May 9, 8:48:52.1am ET